ARTBIO is redefining cancer care by developing a new class of alpha radioligand therapies (ART) and building the ecosystem that maximizes their potential. ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.